Lina Life Secures Exclusive Rights for Cancer Follow-Up Insurance With MRD Testing

Lina Life Insurance is moving to gain an early position in the market with an insurance product that continuously monitors the possibility of recurrence and metastasis after a cancer diagnosis. The product is linked to minimal residual disease testing, focusing on checking signals of cancer cells that may remain after treatment, and Lina Life has secured exclusive usage rights for it. While traditional cancer insurance has largely centered on paying diagnosis benefits, this product highlights a new coverage area: follow-up management for cancer survivors. As insurers pay closer attention to post-diagnosis care needs, competition around coverage that includes recurrence and metastasis monitoring may expand. Source: mk.co.kr